Acute Renal Failure, which is now known as Acute Kidney Injury is characterized by azotemia that progresses over several hours or days, with or without oliguria. ARF is commonly defined as an abrupt decline in renal function, clinically manifesting as a reversible acute increase in nitrogen waste products measured by blood urea nitrogen (BUN) and serum creatinine levels over the course of hours to weeks. The disease leads to the abrupt loss of kidney function, leading to the retention of waste products, electrolyte disturbances, and volume status changes.
Get FREE sample copy at: https://www.delveinsight.com/sample-request/acute-kidney-injury-aki-market
The Acute Kidney Injury (AKI) market report also covers emerging drugs, current treatment practices, Acute Kidney Injury (AKI) market share of the individual therapies, current and forecasted Acute Kidney Injury (AKI) Market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Acute Kidney Injury (AKI) treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Acute Kidney Injury (AKI) Market Key Facts
-
Among the 7MM, the highest incident cases of Acute Kidney Injury (AKI) were recorded in the United States which was 895,078 in 2017. While the lowest incident population of Acute Kidney Injury (AKI) was recorded in Japan.
-
Among the EU5 countries, Germany had the highest AKI diagnosed discharge cases with 82,902 cases followed by France while the least number of cases were observed in Spain in 2017.
-
AKI is common, especially among the elderly (≥ 65). It has been estimated that it occurs during 2–7% of all hospital admissions and at even higher rates in elderly patients.
-
The epidemiology of AKI has been estimated on the basis of the study conducted by Liangos et al., entitled, “Epidemiology and Outcomes of Acute Renal Failure in Hospitalized Patients: A National Survey” which summarized the incidence of AKI patients in the United States using national administrative data and described its impact on hospital length of stay (LOS), patient disposition, and adverse outcomes.
-
According to Fuhrman et al., under the study titled,” Acute kidney injury epidemiology, risk factors, and outcomes in critically ill patients 16-25 years of age treated in an adult intensive care unit”, stage I AKI occurred with the greatest frequency and stage 3 AKI occurred with the lowest frequency in the 16–25-year old age group.
Key Benefits of Acute Kidney Injury (AKI) Market Report
-
Acute Kidney Injury (AKI) market report provides an in-depth analysis of Acute Kidney Injury (AKI) Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major markets, i.e. EU5 (Germany, Italy, Spain, France, and the UK), Japan, and the United States.
-
The Acute Kidney Injury (AKI) market report will help in developing business strategies by understanding the Acute Kidney Injury (AKI) Market trends & developments, key players, and future market competition that will shape and drive the Acute Kidney Injury (AKI) market in the upcoming years.
-
The Acute Kidney Injury (AKI) market report covers Acute Kidney Injury (AKI) current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
-
The report provides a detailed assessment of the Acute Kidney Injury (AKI) market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
Acute Kidney Injury (AKI) Market
The Acute Kidney Injury (AKI) market outlook section of the report helps to build a detailed comprehension of the historic, current and forecasted Acute Kidney Injury (AKI) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.
The report gives a thorough detail of the Acute Kidney Injury (AKI) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Acute kidney injury (AKI) Market Drivers –
-
Robust Pipeline Activity
-
Reimbursement policies
-
Increased incidence of hospitalization
Acute Kidney Injury (AKI) Epidemiology
The Acute Kidney Injury (AKI) epidemiology section covers insights about the historical and current Acute Kidney Injury (AKI) patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Acute kidney injury (AKI) Epidemiology Segmentation –
-
Discharge Diagnosed Cases
-
Total Incident Patient Population
-
Risk Factor Associated AKI Cases
-
Stage-wise Discharged Diagnosed cases
-
Renal Transplantation Associated Delayed Graft Function Cases
Acute Kidney Injury (AKI) Drugs Uptake and Key Market Players
The Acute Kidney Injury (AKI) Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Acute Kidney Injury (AKI) market or expected to get launched in the market during the study period. The analysis covers Acute Kidney Injury (AKI) market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Acute kidney injury (AKI) is frequent and is associated with poor outcomes, including increased mortality, higher risk of chronic kidney disease, and prolonged hospital lengths of stay.
Despite harmonization in clinical definition and staging, identification of novel renal biomarkers for clinical use, and progress in understanding the underlying pathophysiology, there remains a major unmet medical need. The current market persists with various unmet needs related to diagnosis and effective treatment which includes lack of approved therapies for Sepsis AKI, high affordability.
Acute Kidney Injury (AKI) Therapies and Key Companies:
-
EA-230: Exponential Biotherapies
-
bRESCAP: Alloksys
-
ANG-3777 (BB3): Angion Biomedica
-
QPI-1002: Quark Pharmaceuticals
-
recAP: AM Pharma
-
Reltecimod: AtoxBio
-
ASP1128: Astellas Pharma
-
Ruconest (Conestat alfa): Pharming Technologies
-
MB-102: MediBeacon
-
Levosimendan (Simdax): Orion Pharma
And many others
Table of Content
1. Key Insights
2. Executive Summary
3. Acute Kidney Injury (AKI) Competitive Intelligence Analysis
4. Acute Kidney Injury (AKI) Market Overview at a Glance
5. Acute Kidney Injury (AKI) Disease Background and Overview
6. Acute Kidney Injury (AKI) Patient Journey
7. Acute Kidney Injury (AKI) Epidemiology and Patient Population
8. Acute Kidney Injury (AKI) Treatment Algorithm, Current Treatment, and Medical Practices
9. Acute Kidney Injury (AKI) Unmet Needs
10. Key Endpoints of Acute Kidney Injury (AKI) Treatment
11. Acute Kidney Injury (AKI) Marketed Products
12. Acute Kidney Injury (AKI) Emerging Therapies
13. Acute Kidney Injury (AKI) Seven Major Market Analysis
14. Attribute Analysis
15. Acute Kidney Injury (AKI) Market Outlook (7 major markets)
16. Acute Kidney Injury (AKI) Access and Reimbursement Overview
17. KOL Views on the Acute Kidney Injury (AKI) Market.
18. Acute Kidney Injury (AKI) Market Drivers
19. Acute Kidney Injury (AKI) Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.
Get FREE sample copy at: https://www.delveinsight.com/sample-request/acute-kidney-injury-aki-market
Latest Reports By DelveInsight –
Acute Kidney Injury (AKI) Pipeline Insights
Acute Kidney Injury (AKI) Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Acute Kidney Injury (AKI) market.
Gonorrhea Market Insight
DelveInsight’ s “Gonorrhea Market Insights, Epidemiology, and Market Forecast 2030” report provide a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology as well as the Gonorrhea market size, share, trends, and forecast for the seven major markets (i.e. the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/